EUVIMEDEUVIMED entdecken
Crossref

Myo-inositol in the treatment of airways diseases: a minireview

D. Menichini, F. Facchinetti

International Journal of Medical Device and Adjuvant Treatments · 2021-03 · 4

DOI: 10.32113/ijmdat_20213_296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Device and Adjuvant Treatments, 2021-03. Verfasst von D. Menichini und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myo-Inositol (myo-Ins), key molecule participating in several intracellular signaling pathways and physiological processes, has been proven to modulate interleukin-6 (IL-6) levels in chronic inflammatory diseases and to possess endothelial protective properties. Moreover, myo-Ins promotes the maturation of pulmonary surfactant phospholipids, with beneficial effects in the treatment of premature infants with respiratory distress syndrome (RDS). On these premises, myo-Ins has a potential application in the treatment of pulmonary diseases, and it could be successfully used to reduce the complications related to the SARS-CoV-2 pandemic event. Though information about the virus is still scarce, it is becoming evident that the Coronavirus infection triggers an interstitial pneumonia that quickly evolves into a severe RDS, associated with a thrombotic and vascular disease targeting endothelial cells throughout the body. These effects are most probably driven by a disastrous overreaction of the immune system, known as “cytokine storm”, which interests not only lungs but also gut, kidneys, heart, and brain, with platelet-endothelial dysfunction and abnormally rapid life-threatening blood clotting. Given the pathophysiology of the SARS-CoV-2 disease (COVID-19), it could be worth investigating whether myo-Ins properties can mitigate the disease-related complications in terms of surfactant production, modulation of inflammatory cytokines and endothelial protection.

Schlagwörter

il-6myo-inositolrespiratory distress syndromesars-cov-2surfactant

Zitieren

APA

Menichini, D., & Facchinetti, F. (2021). Myo-inositol in the treatment of airways diseases: a minireview. International Journal of Medical Device and Adjuvant Treatments, 4. https://doi.org/10.32113/ijmdat_20213_296

Vancouver

Menichini D, Facchinetti F. Myo-inositol in the treatment of airways diseases: a minireview. International Journal of Medical Device and Adjuvant Treatments. 2021;4. doi:10.32113/ijmdat_20213_296

BibTeX
@article{Menichini2021,
  author = {Menichini, D. and Facchinetti, F.},
  title = {Myo-inositol in the treatment of airways diseases: a minireview},
  journal = {International Journal of Medical Device and Adjuvant Treatments},
  year = {2021},
  volume = {4},
  doi = {10.32113/ijmdat_20213_296}
}
Kostenlos starten →